Updated on 17 July 2013
NPPA: We have only followed the norms prescribed in the DPCO
Singapore: Miffed at Indian government's move to slash prices of essential medicines through the new drug pricing policy, drug makers Cipla and Alembic have now moved court.
The Indian government's direction to replace existing stock with cheaper ones has come under harsh criticism by the industry players, who have now approached the law to resolve the matter.
Cipla and Alembic have reportedly approached the Delhi High Court and Gujarat High Court in India, respectively, challenging the provisions of the new Drug Price Control Order (DPCO) 2013, notified by the government in May.
Mumbai-based Cipla has made its discontent clear over the government's direction to replace stocks in the market with those carrying reduced maximum retail prices (MRPs) within 45 days of the new price notification by the National Pharmaceutical Pricing Authority (NPPA).
Meanwhile, Alembic too, has challenged NPPA's mechanism for computation of one percent market share while determining the price cap.